Andrew Watt

"To Treat or not To Treat": Informing the Decision for Disease-Modifying Therapy in Late-Stage Alzheimer's Disease

Andrew D Watt, Nicole L Jenkins, Gawain McColl, Steven Collins, Patricia M Desmond

Journal article  |  2019  |  JOURNAL OF ALZHEIMERS DISEASE

Rosen et al. thoughtfully extend the ethical discussion surrounding disease-modifying therapies in late-stage Alzheimer's disease ..

Ethical Issues in the Treatment of Late-Stage Alzheimer's Disease

Andrew D Watt, Nicole L Jenkins, Gawain McColl, Steven Collins, Patricia M Desmond

Journal article  |  2019  |  JOURNAL OF ALZHEIMERS DISEASE

There is hope that the continuing efforts of researchers will yield a disease-modifying drug for Alzheimer's disease. Such a drug ..

P2-053: ENGINEERED ANTIBODIES TO TREAT OR PREVENT ALZHEIMER'S DISEASE

Gabriela AN Crespi, Andrew D Watt, Nancy C Hancock, Tracy Nero, Stefan Hermans, Kevin J Barnham, Michael W Parker, Luke A Miles

Journal article  |  2018  |  Alzheimer's & Dementia

High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease

Maxime Francois, Michael F Fenech, Philip Thomas, Maryam Hor, Alan Rembach, Ralph N Martins, Stephanie R Rainey-Smith, Colin L Masters, David Ames, Christopher C Rowe, S Lance Macaulay, Andrew F Hill, Wayne R Leifert

Journal article  |  2016  |  CURRENT ALZHEIMER RESEARCH

Alzheimer's disease (AD) is a degenerative brain disorder and is the most common form of dementia. Minimally invasive approaches a..

Isolation of brain derived extracellular vesicles for studying pathobiology & identifying biomarkers of neurodegenerative disease

L Vella, B Scicluna, L Cheng, K Perez, A Watt, C Masters, K Barnham, A Hill

Conference Proceedings  |  2015  |  JOURNAL OF NEUROCHEMISTRY

Peripheral alpha-Defensins 1 and 2 are Elevated in Alzheimer's Disease

Andrew D Watt, Keyla A Perez, Ching-Seng Ang, Paul O'Donnell, Alan Rembach, Kelly K Pertile, Rebecca L Rumble, Brett O Trounson, Christopher J Fowler, Noel G Faux, Colin L Masters, Victor L Villemagne, Kevin J Barnham

Journal article  |  2015  |  JOURNAL OF ALZHEIMERS DISEASE

Biomarkers enabling the preclinical identification of Alzheimer's disease (AD) remain one of the major unmet challenges in the fie..

Anti-A beta antibody target engagement: a response to Siemers et al.

Andrew D Watt, Gabriela AN Crespi, Russell A Down, David B Ascher, Adam Gunn, Keyla A Perez, Catriona A McLean, Victor L Villemagne, Michael W Parker, Kevin J Barnham, Luke A Miles

Journal article  |  2014  |  ACTA NEUROPATHOLOGICA

An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation

Alan Rembach, Andrew D Watt, William J Wilson, Stephanie Rainey-Smith, Kathryn A Ellis, Christopher C Rowe, Victor L Villemagne, S Lance Macaulay, Ashley I Bush, Ralph N Martins, David Ames, Colin L Masters, James D Doecke

Journal article  |  2014  |  JOURNAL OF NEUROIMMUNOLOGY

Inflammation is a hallmark of Alzheimer's disease (AD). Whether directly involved in the pathogenesis, or a downstream consequence..

Do current therapeutic anti-A beta antibodies for Alzheimer's disease engage the target?

Andrew D Watt, Gabriela AN Crespi, Russell A Down, David B Ascher, Adam Gunn, Keyla A Perez, Catriona A McLean, Victor L Villemagne, Michael W Parker, Kevin J Barnham, Luke A Miles

Journal article  |  2014  |  ACTA NEUROPATHOLOGICA

Reducing amyloid-β peptide (Aβ) burden at the pre-symptomatic stages of Alzheimer's disease (AD) is currently the advocated clinic..

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

Alan Rembach, Noel G Faux, Andrew D Watt, Kelly K Pertile, Rebecca L Rumble, Brett O Trounson, Christopher J Fowler, Blaine R Roberts, Keyla A Perez, Qiao-Xin Li, Simon M Laws, Kevin Taddei, Stephanie Rainey-Smith, Joanne S Robertson, Manu Vandijck, Hugo Vanderstichele, Kevin J Barnham, Kathryn A Ellis, Cassandra Szoeke, Lance Macaulay, et al.

Journal article  |  2014  |  ALZHEIMERS & DEMENTIA

BACKGROUND: A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimer's disease (AD). METHODS: Plasma..